Home  |  Contact

UniProtKB/Swiss-Prot O95140: Variant p.Thr362Met

Mitofusin-2
Gene: MFN2
Variant information

Variant position:  362
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  US
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Threonine (T) to Methionine (M) at position 362 (T362M, p.Thr362Met).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (T) to medium size and hydrophobic (M)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In CMT2A2B; unknown pathological significance.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  362
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  757
The length of the canonical sequence.

Location on the sequence:   ERRFEECISQSAVKTKFEQH  T VRAKQIAEAVRLIMDSLHMA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ERRFEECISQSAVKTKFEQHTVRAKQIAEAVRLIMDSLHMA

Mouse                         ERQFEECISQSAVKTKFEQHTVRAKQIAEAVRLIMDSLHIA

Rat                           ERRFEECISQSAVKTKFEQHTVRAKQIAEAVRLIMDSLHIA

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 757 Mitofusin-2
Topological domain 1 – 604 Cytoplasmic
Region 359 – 385 Part of a helix bundle domain, formed by helices from N-terminal and C-terminal regions
Helix 331 – 397


Literature citations

Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations.
Polke J.M.; Laura M.; Pareyson D.; Taroni F.; Milani M.; Bergamin G.; Gibbons V.S.; Hovdulden H.; Chavdmley S.C.; Blake J.; Devile C.; Sandford R.; Sweeney M.G.; Davis M.B.; Reilly M.M.;
Neurology 77:168-173(2011)
Cited for: INVOLVEMENT IN CMT2A2B; VARIANTS CMT2A2B LYS-38 DEL; SER-216 AND MET-362;

Severe early-onset axonal neuropathy with homozygous and compound heterozygous MFN2 mutations.
Nicholson G.A.; Magdelaine C.; Zhu D.; Grew S.; Ryan M.M.; Sturtz F.; Vallat J.M.; Ouvrier R.A.;
Neurology 70:1678-1681(2008)
Cited for: VARIANTS CMT2A2B VAL-164; ASN-214; MET-362; ARG-390 AND TRP-707;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.